Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter April 18, 2023

The new synthetic benzimidazole opioid etonitazepipne: an emerging fatal harm and a challenge for laboratory medicine

  • Annagiulia Di Trana , Nunzia La Maida , Rino Froldi , Roberto Scendoni , Francesco Paolo Busardò EMAIL logo and Simona Pichini

Corresponding author: Professor Francesco Paolo Busardò, Department of Excellence of Biomedical Science and Public Health, Università Politecnica delle Marche, Via Conca 71, 60126 Ancona, Italy, E-mail:

Funding source: Italian Department of Antidrug policies

Award Identifier / Grant number: no number

  1. Research funding: The study is partially funded by the project “Implementation of the identification and study of the effects of NPS: Development of a multicenter research to enhance the database of the National drug Addiction Observatory and the Early Warning System” and by the project “National Early Warning System on Drugs (SNAP)” following the Italian Department of Antidrug policies.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: Not applicable.

References

1. Fischer, B. Comment the continuous opioid death crisis in Canada: changing characteristics and implications for path options forward. Lancet Reg Heal – Am [Internet] 2023;19:100437. https://doi.org/10.1016/j.lana.2023.100437.Search in Google Scholar PubMed PubMed Central

2. Post, LA, Lundberg, A, Moss, CB, Brandt, CA, Quan, I, Han, L, et al.. Geographic trends in opioid overdoses in the US from 1999 to 2020. JAMA Netw Open 2022;5:E2223631. https://doi.org/10.1001/jamanetworkopen.2022.23631.Search in Google Scholar PubMed PubMed Central

3. Di Trana, A, Pichini, S, Pacifici, R, Giorgetti, R, Busardò, FP. Synthetic benzimidazole opioids: the emerging health challenge for European drug users. Front Psychiatr 2022;13:858234. https://doi.org/10.3389/fpsyt.2022.858234.Search in Google Scholar PubMed PubMed Central

4. Calello, DP, Aldy, K, Jefri, M, Nguyen, TAT, Krotulski, A, Logan, B, et al.. Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose. Front Psychiatr 2022;13:858234. https://doi.org/10.1080/15563650.2022.2084406.Search in Google Scholar PubMed PubMed Central

5. Vandeputte, MM, Krotulski, AJ, Walther, D, Glatfelter, GC, Papsun, D, Walton, SE, et al.. Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole ‘nitazene’ synthetic opioid. Arch Toxicol 2022;96:1845–63. https://doi.org/10.1007/s00204-022-03276-4.Search in Google Scholar PubMed

6. Marchei, E, Ferri, MA, Torrens, M, Farré, M, Pacifici, R, Pichini, S, et al.. Ultra-high performance liquid chromatography-high resolution mass spectrometry and high-sensitivity gas chromatography-mass spectrometry screening of classic drugs and new psychoactive substances and metabolites in urine of consumers. Int J Mol Sci 2021;22. https://doi.org/10.3390/ijms22084000.Search in Google Scholar PubMed PubMed Central

7. EMCDDA. New psychoactive substances: 25 years of early warning and response in Europe; 2022. Available from: https://www.emcdda.europa.eu/publications/rapid-communication/update-eu-early-warning-system-2022_en.Search in Google Scholar

8. Fischer, B, Pang, M, Tyndall, M. The opioid death crisis in Canada: crucial lessons for public health. Lancet Public Health 2019;4:e81–2. https://doi.org/10.1016/s2468-2667(18)30232-9.Search in Google Scholar

9. Zaami, S, Busardò, FP, Pichini, S, Pacifici, R, Marinelli, E. The value of toxicological and forensic analyses in the global challenge to health risks caused by new psychoactive substances. Eur Rev Med Pharmacol Sci 2019;23:6008–10. https://doi.org/10.26355/eurrev_201907_18409.Search in Google Scholar PubMed

Received: 2023-02-22
Accepted: 2023-03-31
Published Online: 2023-04-18
Published in Print: 2023-09-26

© 2023 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 12.6.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2023-0186/html
Scroll to top button